Document:

Exhibit

Exhibit 4.2

Unless this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”), to the Company or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as is requested by an authorized representative of DTC (and any payment is made to Cede & Co. or to such other nominee as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein. 
 
	
			
	 
	 
	 

	REGISTERED
	 
	REGISTERED

Consolidated Edison Company of New York, Inc. 
4.65% DEBENTURES, SERIES 2018 E 
 

	
				
	INTEREST RATE
4.65% per annum
	MATURITY DATE
December 1, 2048
	CUSIP
209111 FT5
	CERTIFICATE NUMBER
R-

REGISTERED HOLDER: Cede & Co. 

PRINCIPAL SUM:  

CONSOLIDATED EDISON COMPANY OF NEW YORK, INC., a New York corporation (hereinafter called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to the registered holder named above or registered assigns, on the maturity date stated above, unless redeemed prior thereto as hereinafter provided, the principal sum stated above and to pay interest thereon from November 30, 2018, or from the most recent interest payment date to which interest has been duly paid or provided for, initially on June 1, 2019, and thereafter semi-annually on June 1 and December 1 each year, at the interest rate stated above, until the date on which payment of such principal sum has been made or duly provided for. The interest so payable on any interest payment date will be paid to the person in whose name this Debenture is registered at the close of business on the fifteenth day, whether or not a business day, of the calendar month next preceding such interest payment date, except as otherwise provided in the Indenture. 
The principal of this Debenture, when due and payable, shall, upon presentation and surrender hereof, be paid at The Bank of New York Mellon, Corporate Trust Operations, 111 Sanders Creek Parkway, East Syracuse, New York 13057, or at the office of any paying agent subsequently appointed pursuant to the Indenture. The interest on this Debenture, when due and payable, shall be paid at The Bank of New York Mellon or at the office of any paying agent subsequently appointed pursuant to the Indenture, or at the option of the Company, by check mailed to the address of the registered holder hereof or registered assigns as such address shall appear in the Security Register. All such payments shall be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. 

1

This Debenture is one of a duly authorized series of an issue of unsecured debt securities of the Company designated as its 4.65% Debentures, Series 2018 E (hereinafter called the “Debentures”), issued and to be issued under an Indenture dated as of December 1, 1990, between the Company and The Bank of New York Mellon (formerly known as The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly known as JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank (successor to The Chase Manhattan Bank (National Association)))))), as Trustee (hereinafter called the “Trustee”, which term includes any successor trustee under the Indenture), as amended and supplemented by the First Supplemental Indenture, dated as of March 6, 1996, and the Second Supplemental Indenture, dated as of June 23, 2005 (the Indenture, as so amended and supplemented is hereinafter called the “Indenture”). The Debentures shall be issued in an initial aggregate principal amount of $600,000,000. The Company may at any time, without the consent of the holders of the Debentures, issue additional Debentures that will be part of the same series of debt securities as, rank equally and ratably with, and have the same interest rate, maturity and other terms (except for the issue date, the issue price and, if applicable, the first interest payment date) as, the Debentures initially issued.  Reference is made to the Indenture and any supplemental indenture thereto for the provisions relating, among other things, to the respective rights of the Company, the Trustee and the holders of the Debentures, and the terms on which the Debentures are, and are to be, authenticated and delivered. 

At any time prior to June 1, 2048  (the “Par Call Date”), the Company may redeem the Debentures in whole or in part, at its option, at a redemption price equal to the greater of (1) 100% of the principal amount of the Debentures being redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon that would be due if the Debentures matured on the Par Call Date (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below) plus 25 basis points, plus, in either case, accrued interest on the principal amount being redeemed to, but not including, the redemption date.  At any time on or after the Par Call Date, the Company may redeem the Debentures in whole or in part, at its option at a redemption price equal to 100% of the principal amount of the Debentures being redeemed plus accrued interest on the principal amount being redeemed to, but not including, the redemption date.

“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of the Debentures being redeemed (assuming, for this purpose, that the Debentures matured on the Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such Debentures. 
“Comparable Treasury Price” means, with respect to any redemption date, (1) the average of the Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, or (2) if the Company obtains fewer than five of such Reference Treasury Dealer Quotations, the average of all such quotations. 
“Independent Investment Banker” means one of the Reference Treasury Dealers (as defined below) appointed by the Trustee after consultation with the Company. 

“Reference Treasury Dealer” means each of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mizuho Securities USA LLC, Scotia Capital (USA) Inc. and Wells Fargo Securities, LLC or their respective affiliates and successors, and one other primary U.S. Government securities dealer in the United States (a “Primary Treasury Dealer”) selected by MUFG Securities Americas Inc. If any Reference Treasury Dealer shall cease to be a Primary Treasury Dealer, the Company will substitute another Primary Treasury Dealer for that dealer. 
“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Company, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Company by such Reference Treasury Dealer at 3:30 p.m. New York time on the third business day preceding such redemption date. 

2

“Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date. 
Unless the Company defaults in payment of the redemption price, on and after the redemption date interest will cease to accrue on the Debentures or portions thereof called for redemption. 
If an Event of Default (as defined in the Indenture) shall have occurred and be continuing with respect to the Debentures, the principal hereof may be declared, and upon such declaration shall become, due and payable, in the manner, with such effect and subject to the conditions provided in the Indenture. Any such declaration may be rescinded by holders of a majority in principal amount of the outstanding Debentures if all Events of Default with respect to the Debentures (other than the non-payment of principal of the Debentures which shall have become due by such declaration) shall have been remedied. 

The Indenture contains provisions permitting the Company and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of the Debentures at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures adding any provisions to the Indenture or to any supplemental indenture with respect to the Debentures, or modifying in any manner the rights of the holders of the Debentures; provided, however, that no such supplemental indenture shall (i) extend the maturity of any Debenture, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or make the principal thereof, or interest thereon, payable in any coin or currency other than that provided in the Debentures without the consent of the holder of each Debenture so affected, or (ii) reduce the aforesaid principal amount of Debentures, the holders of which are required to consent to any such supplemental indenture without the consent of the holders of all Debentures then outstanding. 
The Debentures are issuable as registered Debentures only, in the denomination of $2,000 and any integral multiples of $1,000 approved by the Company, such approval to be evidenced by the execution thereof. 
This Debenture is transferable by the registered holder hereof in person or by his attorney duly authorized in writing on the books of the Company at the office or agency to be maintained by the Company for that purpose, but only in the manner, subject to the limitations and upon payment of any tax or governmental charge for which the Company may require reimbursement as provided in the Indenture, and upon surrender and cancellation of this Debenture. Upon any registration of transfer, a new registered Debenture or Debentures, of authorized denomination or denominations, and in the same aggregate principal amount, will be issued to the transferee in exchange therefor. 
The Company, the Trustee, any paying agent and any Security registrar may deem and treat the registered holder hereof as the absolute owner of this Debenture (whether or not this Debenture shall be overdue and notwithstanding any notations of ownership or other writing hereon made by anyone other than the Security registrar) for the purpose of receiving payment of or on account of the principal hereof and interest due hereon as herein provided and for all other purposes, and neither the Company nor the Trustee nor any paying agent nor any Security registrar shall be affected by any notice to the contrary. 
No recourse shall be had for the payment of the principal of or interest on this Debenture, or for any claim based hereon, or otherwise in respect hereof, or based on or in respect of the Indenture or any indenture supplemental thereto, against any incorporator or against any past, present or future stockholder, officer or member of the Board of Trustees, as such, of the Company, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issue hereof, expressly waived and released. 
This Debenture shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall be construed in accordance with the laws of the State of New York. 

3

All terms used in this Debenture which are defined in the Indenture and not defined herein shall have the meanings assigned to them in the Indenture. 
This Debenture shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose until the certificate of authentication on the face hereof is manually signed by the Trustee. 
 
IN WITNESS WHEREOF, the Company has caused this Debenture to be signed by the manual or facsimile signatures of the Senior Vice President and Chief Financial Officer and the Vice President and Treasurer of the Company, and a facsimile of its corporate seal to be affixed or reproduced hereon. 
 
	
			
	 
	 
	 

	 
	 
	CONSOLIDATED EDISON COMPANY OF NEW YORK, INC.

	 
	 

	 
	 
	 

	By
	   

	 
	 
	Senior Vice President and Chief Financial Officer

	 
	 

	                                                                           By
	 
	 

	 
	 

	 
	 
	Vice President and Treasurer

SEAL 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated herein 
issued under the Indenture described herein. 
 
	
			
	 
	 
	 

	 
	 
	THE BANK OF NEW YORK MELLON,

	 
	 
	as Trustee

	 
	 

	                                                                                    By
	 
	 

	 
	 

	 
	 
	Authorized Signatory

Dated: 
 

4Exhibit 10.1

 

 

	September 28, 2018

	 
	Joao Siffert, MD	 

 

Dear Joao,

  

I am pleased
to offer you the position of Executive Vice President, Head of Research & Development with Abeona Therapeutics Inc. (the “Company”)
reporting to our Chief Executive Officer (“CEO”), effective October 24, 2018 (the "Effective Date").

 

		1.	Duties.

 

As the Head of Research & Development,
your general duties shall include, but not be limited to:

 

		·	Leadership of the Research & Development (“R&D”)
organization including oversight of the product development team (“Research”), Clinical Operations, Medical
Affairs and Regulatory Affairs

		·	Working with Business Development and Commercial to develop the preclinical
and clinical strategy

		·	Providing vision and plan for shaping the Company to delivering future
pipeline growth

		·	Ensuring that work is conducted in compliance with Company guidelines
applicable laws and regulations and industry standards

		·	Ensuring resource levels, competencies, skills and knowledge are in
place and balanced to support achievement of R&D targets across R&D

		·	Supporting of Bids & Proposals work streams

		·	Accountable for budget, schedule, scope, quality and delivery of all
R&D projects

		·	Building the delivery structure for R&D projects

		·	Leading the R&D team to meet the Company strategy through tasks
and project delivery

		·	Development and management of the R&D Governance and Plans

		·	Establishing compliance tools, trainings and processes in your team

		·	Line management and career development responsibilities

		·	Ensuring the department is using industry best practice in the delivery
of projects and products

 

		2.	Compensation and Benefits.

 

During your
employment, you will receive a base salary of $450,000 USD, payable in accordance with the regular payroll practices of the Company
(“Base Salary”). During your employment, you may be considered for an annual discretionary bonus (“Annual
Bonus”) in addition to your Base Salary with a target of 45% of your Base Salary (“Target Annual Bonus Opportunity”).
Annual Bonus compensation in any year, if any, will be determined in the Company sole discretion and shall be based on your performance
and that of the Company, as well as market factors, in accordance with a general bonus program established by the Compensation
Committee (the “Compensation Committee”) of the Board of Directors of the Company (the “Board”).
Except as provided below under Section 3 in the event of certain terminations of your employment, to be eligible to receive an
Annual Bonus for any year, if any, you must be employed in good standing on the date that the Annual Bonus is paid. You will receive
a sign-on bonus of $ 190,000 USD with $95,000 paid within thirty (30) days following the Effective Date and $95,000 paid 120 days
after the Effective Date, provided you are employed on such dates. This sign-on bonus is to encourage you to accept employment
with the Company and is not payment for any work performed or services rendered by you. Your right to retain the sign-on bonus,
therefore, shall not vest until you have completed one (1) year of service with the Company. Accordingly, this sign-on bonus is
repayable immediately should your employment terminate for any reason, including your resignation, within one (1) year following
the Effective Date.

 

     

     

    

 

Subject
to Compensation Committee approval, at the first regularly scheduled meeting of the Compensation Committee after the Effective
Date, you will be granted a stock option under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the “Plan”)
to purchase 180,000 shares of Company common stock (the "Initial Option"). The Initial Option will vest over a
forty-eight (48) month period, with one quarter (25%) vesting on the one-year anniversary of the Effective Date and the remaining
seventy-five percent (75%) of the Initial Option vesting in equal monthly installments thereafter over the remaining thirty-six
(36) months, commencing with the first month following the first anniversary of the Effective Date, and subject to (i) your continued
employment with the Company and/or its affiliates through to the applicable vesting dates, and (ii) the terms and conditions of
the Plan and the agreement memorializing the terms of the Initial Option. If you remain continuously employed from the Effective
Date through the date of a Change in Control (as defined below), any unvested portion of the Initial Option as of the date of the
Change in Control shall become fully vested immediately prior to the date of the Change in Control. Pursuant to the terms of the
Plan, the exercise price of the Initial Option will be the fair market value of the Company’s common stock on the date of
the grant.

 

Subject
to Compensation Committee approval, in January 2019, you will be granted a stock option under the Plan to purchase 60,000 shares
of Company common stock ("Subsequent Option"). The Subsequent Option will vest over a forty-eight (48) month period,
with one quarter (25%) vesting on the one-year anniversary of the date of grant and the remaining seventy-five percent (75%) of
the Subsequent Option vesting in equal monthly installments thereafter over the remaining thirty-six (36) months, commencing with
the first month following the first anniversary of the date of grant, and subject to (i) your continued employment with the Company
and/or its affiliates through to the applicable vesting dates, and (ii) the terms and conditions of the Plan and the agreement
memorializing the terms of the Subsequent Option. If you remain continuously employed from the Effective Date through the date
of a Change in Control, any unvested portion of the Subsequent Option as of the date of the Change in Control shall become fully
vested immediately prior to the date of the Change in Control. Pursuant to the terms of the Plan, the exercise price of the Subsequent
Option will be the fair market value of the Company’s common stock on the date of the grant.

 

During your
employment, you will be eligible to participate in such health and other group insurance and other employee benefit plans and programs
of the Company as in effect from time to time on the same basis as other senior executives of the Company. Your participation will
be subject to the terms of the applicable plan documents and generally applicable Company policies. The Company reserves the right
to amend or terminate any employee benefit plans, programs and policies in its discretion after the Effective Date.

 

You will
be entitled to twenty (20) days of paid time off (vacation days plus sick time/personal time) per year accrued at a rate in accordance
with the Company’s policies from time to time in effect, in addition to holidays observed by the Company. Paid time off may
be taken at such times and intervals as you shall determine, subject to the business needs of the Company and the responsibilities
of your position.

 

    2

     

    

 

		3.	Employment Termination.

 

The Company may terminate
your employment for any reason, and you may voluntarily terminate your employment hereunder for any reason, in each case at any
time upon written notice to the other party (the date on which your employment terminates for any reason is herein referred to
as the “Termination Date”). Upon your termination of employment for any reason, you (or your beneficiary or estate, as applicable, in the event of your death) will be entitled to (i) payment of any Base Salary earned
but unpaid through the Termination Date, (ii) any accrued unused vacation days, (iii) additional vested benefits (if any) in accordance
with the applicable terms of applicable Company arrangements, and (iv) any unreimbursed expenses in accordance with the Company’s
business expense reimbursement policies (collectively, the “Accrued Amounts”); provided, however,
that if your employment hereunder is terminated (a) by the Company without Cause (as defined below), (b) by you for Good Reason
(as defined below), (c) on account of your death or (d) by the Company on account of your Disability (as defined below), then you
will be eligible to receive any Annual Bonus awarded in a prior year, but not yet paid or due to be paid.

 

If your employment
is terminated (a) by the Company other than for Cause, death or Disability or (b) by you for Good Reason, in addition to the Accrued
Amounts, you will be entitled to: (i) a payment equal to the sum of your Base Salary plus your Target Annual Bonus Opportunity
(such amount, the “Severance Amount”); (ii) a payment equal to the premiums that you would pay if you elected
continued health coverage under the Company’s health plan for you and your eligible dependents for the twelve (12) month
period following the Termination Date, less the applicable active employee rate, which premiums will be calculated based on the
rate determined under the COBRA rate in effect on the Termination Date (“Medical Benefit Payment”); (iii) a
pro-rata Annual Bonus, which pro-rated Annual Bonus shall be determined by multiplying the full year Annual Bonus that would otherwise
have been awarded to you, based upon the achievement of the applicable performance goals for the year in which the Termination
Date occurs (without any exercise of negative discretion disproportionate to any such exercise respecting other executives and
all subjective performance requirements deemed fully satisfied), multiplied by a fraction, the numerator of which is the number
of days during which you were employed by the Company in the year in which the Termination Date occurs and the denominator of which
is three hundred sixty-five (365); and (iv) accelerated vesting equivalent to twelve (12) months of continued employment from the
Termination Date (disregarding such termination for such purpose) with respect to all unvested equity and any other long-term incentive
awards granted to you and then outstanding on the Termination Date; provided, that, any delays in the settlement
or payment of such awards that are set forth in the applicable award agreement and that are required under Section 409A of the
Internal Revenue Code, as amended (the “Code”), and the Treasury Regulations thereunder (“Section 409A”)
shall remain in effect. The Company’s obligations to make the payments and provide the benefits set forth in (i) –
(iv) in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your
execution and nonrevocation of a release of claims in favor of the Company and its affiliates in a form provided by the Company
(“Release”). Notwithstanding any provision to the contrary herein (other than the provisions of Section 7 below),
and without limitation of any remedies to which the Company may be entitled, (A) the Severance Amount shall be paid in installments
in accordance with the Company’s regular payroll practices during a twelve (12) month period commencing within sixty (60)
days following the Termination Date (with the first such payment to include all installment amounts from the Termination Date),
(B) the Medical Benefit Payment will be made in a lump sum within sixty (60) days following the Termination Date and (C) the pro-rated
Annual Bonus shall be paid to you in the ordinary course at the same time annual bonuses are paid to other senior executives, but
in no event later than March 15 of the year following the year in which the Termination Date occurs; provided, that,
the Release is effective.

 

    3

     

    

 

Notwithstanding any
other provision contained herein, if your employment hereunder is terminated by you for Good Reason or by the Company without Cause
(other than on account of your death or Disability), in each case within twelve (12) months following a Change in Control, you
will be entitled to receive the Severance Amount, the Medical Benefit Payment, and the pro-rata Annual Bonus, as provided above,
except that (i) if the Change in Control is a “change in control event” as defined under Section 409A, the Severance
Amount shall be payable in a lump sum within sixty (60) days following the Termination Date; and (ii) notwithstanding the
terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options/stock appreciation
rights granted to your during your employment with the Company shall become fully vested and exercisable and will remain exercisable
for six (6) months following the Termination Date and all outstanding equity-based and other long-term compensation awards, other
than stock options/stock appreciation rights, shall become fully vested and the restrictions thereon shall lapse; provided,
that, any delays in the settlement or payment of such awards that are set forth in the applicable award agreement and that
are required under Section 409A shall remain in effect. The Company’s obligations to provide the payments and benefits described
in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your execution
and delivery to the Company of an effective Release.

 

The foregoing payments
and benefits upon termination of your employment shall constitute the exclusive severance payments and benefits due to you upon
a termination of your employment.

 

Upon your termination
of employment with the Company for any reason, you will be deemed to have resigned, as of the Termination Date, from all positions
you then hold with the Company and its affiliates.

 

Following the termination
of your employment with the Company for any reason, you will reasonably cooperate with the Company upon reasonable request of the
CEO or the Board or and be reasonably available to the Company (taking into account your other business endeavors) with respect
to matters arising out of your services to the Company and its subsidiaries, including, in connection with any legal proceeding,
providing testimony and affidavits; provided, that, the Company shall make reasonable efforts to minimize disruption
of your other activities. The Company shall reimburse you for reasonable expenses incurred in connection with such cooperation.

 

For purposes of this
offer letter, the following terms have the following meanings:

 

(i)       “Cause”
shall mean: (a) your substantial failure to perform your duties (other than any such failure resulting from incapacity due to physical
or mental disability) that continues for fifteen (15) calendar days after written notice from the Company; (b) your failure to
comply with any valid and legal directive of the CEO or the Board (as applicable) that continues for fifteen (15) calendar days
after written notice from the Company; (c) your engagement in dishonesty, illegal conduct, or misconduct (or the discovery of your
having engaged in such conduct), which, in each case, materially harms or is reasonably likely to materially harm the Company or
its subsidiaries; (d) your embezzlement, misappropriation, or fraud, whether or not related to your employment with the Company;
(e) your conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony; (f) your willful violation of
a material policy of the Company; (g) your willful or grossly negligent unauthorized disclosure of Confidential Information (as
defined below); or (h) your material breach of any material obligation under this offer letter or any other written agreement between
you and the Company that continues for fifteen (15) calendar days after written notice from the Company (if such breach is reasonably
curable); or (i) any willful material failure by you to comply with the Company’s written policies or written rules, as they
may be in effect from time to time.

 

(ii)       “Change
in Control” shall have the meaning defined in subparagraph (ii) of the definition of such term under the Appendix in
the Plan as in effect on the date hereof.

 

    4

     

    

 

(iii)       “Disability”
shall occur, subject to applicable law, when you are entitled to receive long-term disability benefits under the Company’s
long-term disability plan, or if there is no such plan, your inability, due to physical or mental incapacity, to perform the essential
functions of your job for one hundred eighty (180) calendar days out of any three hundred sixty-five (365) day period or one hundred
twenty (120) consecutive calendar days. Any question as to the existence of your Disability as to which you and the Company cannot
agree shall be determined in writing by a qualified independent physician mutually acceptable to you and the Company. If you and
the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians
shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company
and you shall be final and conclusive for all purposes of this offer letter.

 

(iv)       “Good
Reason” shall mean the occurrence of any of the following, in each case without your written consent: (a) a material
reduction of at least ten percent (10%) of your Base Salary other than a general reduction in Base Salary that affects all similarly
situated executives in substantially the same position; (b) a material reduction of at least thirty percent (30%) of the Target
Annual Bonus Opportunity other than a general reduction in the Target Annual Bonus Opportunity that affects all similarly situated
executives in substantially the same position; (c) a permanent relocation of your principal place of employment by more than thirty-five
(35) miles; (d) any material breach by the Company of any material provision of this offer letter; or (e) a material adverse change
in your title, authority, duties, or responsibilities (including the reporting structure applicable to you, other than temporarily
while you are physically or mentally incapacitated); provided, however, that you cannot terminate your employment
for Good Reason unless you have provided written notice to the Company of the existence of the circumstances providing grounds
for termination for Good Reason within sixty (60) calendar days following the initial existence of such grounds and the Company
has had thirty (30) calendar days from the date on which such notice is provided to cure such circumstances. If you do not terminate
your employment for Good Reason within sixty (60) calendar days after expiration of the cure period (in which the Company shall
not have so cured such grounds), then you will be deemed to have waived your right to terminate for Good Reason with respect to
such grounds.

 

		4.	Restrictive Covenants.

 

This offer
of employment is contingent on your signing the Company’s standard Employee Confidentiality, Non-competition, Policy on Insider
Trading, Whistle Blower Policy, Code of Ethics, Proprietary Information Agreement, attached hereto as Exhibit A, the terms
of which are incorporated by reference.

 

		5.	Conditions of Employment.

 

This offer
of employment is contingent on you providing an I-9 Employment Verification Form. You will be required to submit documentation
that establishes identity and employment eligibility in accordance with the US Immigration and Naturalization requirements, if
appropriate. The offer of employment contained in this offer letter, and your continued employment, is contingent upon and subject
to a satisfactory background and reference check (which you hereby authorize), including but not limited to a confirmation of your
stated credentials. It will be in the Company’s sole discretion at any time to determine the scope of the background and
reference check, whether and when to conduct or update such background check and reference check and whether such check is satisfactory.

 

		6.	At-Will Employment.

 

Your employment
with the Company is at-will. This means that you will have the right to terminate your employment relationship with the Company
at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with you at any
time for any reason.

 

    5

     

    

 

		7.	Section 409A.

 

To the extent
applicable, it is intended that this offer letter (including all amendments hereto, if any) either meets the requirements for exclusion
from coverage under Section 409A, or alternatively complies with the requirements of Section 409A, so that the income inclusion
provisions of Section 409A(a)(1) of the Code do not apply to you. This offer letter shall be interpreted and administered in a
manner consistent with this intent.

 

To the extent
that payment of amounts under this offer letter that are subject to Section 409A are payable upon your termination of employment,
such amounts shall only be payable if such termination also constitutes a "separation from service," within the meaning
of Section 409A, from the Company and its affiliates. If you are deemed on the date of your separation from service to be a "specified
employee" (within the meaning of Section 409A(a)(2)(B) of the Code) of the Company, then, notwithstanding any other provision
herein, with regard to any payment that is "nonqualified deferred compensation" subject to Section 409A and that is payable
on account of your "separation from service," such payment shall not be made prior to the earlier of (i) the expiration
of six (6) months following the date of your separation from service, and (ii) the date of your death, following which all payments
so delayed shall be paid to you in a lump sum without interest.

 

Any taxable
reimbursement of business or other expenses provided for under this offer letter that is subject to Section 409A shall be subject
to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible
for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end
of the year after the year in which such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation
or exchange for another benefit.

 

In applying
Section 409A to amounts paid pursuant to this offer letter, each payment shall be treated as a separate payment and any right to
a series of installment payments under this offer letter shall be treated as a right to a series of separate payments. Whenever
a payment under this offer letter specifies a payment period within a specified number of days, the actual date of payment within
the specified period shall be within the sole discretion of the Company. If the consideration and revocation period for the Release
spans two taxable years and any amount hereunder is “nonqualified deferred compensation" subject to Section 409A and
payable on account of your separation from service, such payment shall not be made or commence until the second taxable year.

 

		8.	Section 280G.

 

In the event
of a change in ownership or control under Section 280G of the Code, if it shall be determined that any payment or distribution
in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether paid or payable
or distributed or distributable pursuant to the terms of this offer letter or otherwise (a “Payment”), would
constitute an “excess parachute payment” within the meaning of Section 280G of the Code, the aggregate present value
of the Payments under this offer letter shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only
if the Accounting Firm (described below) determines that the reduction will provide you with a greater net after-tax benefit than
would no reduction. No reduction shall be made unless the reduction would provide you with a greater net after-tax benefit. The
determinations under this Section 8 shall be made as follows:

 

(i)       The
“Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present value of
Payments under this offer letter without causing any Payment under this offer letter to be subject to the Excise Tax (defined below),
determined in accordance with Section 280G(d)(4) of the Code. The term “Excise Tax” means the excise tax imposed
under Section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.

 

    6

     

    

 

(ii)       Payments
under this offer letter shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic
value deliverable to you. Where more than one payment has the same value for this purpose and they are payable at different times,
they will be reduced on a pro-rata basis. Only amounts payable under the offer letter shall be reduced pursuant to this Section.

 

(iii)       All
determinations to be made under this Section shall be made by an independent certified public accounting firm selected by the Company
and agreed to by you immediately prior to the change in ownership or control transaction (the “Accounting Firm”).
The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and you within ten (10)
days of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company and you. All of the fees
and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the Company.

 

		9.	Miscellaneous.

 

All amounts
paid to you under this offer letter during or following your employment shall be subject to withholding and other employment taxes
imposed by applicable law, and the Company shall withhold from any payments under this offer letter all federal, state and local
taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely responsible
for the payment of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.

 

This offer
letter may be executed by .pdf or facsimile signatures in any number of counterparts, each of which shall be deemed an original,
but all such counterparts shall together constitute one and the same instrument.

 

From and
after the Effective Date, this offer letter (including Exhibit A hereto) constitutes the entire agreement between you and
the Company, and supersedes all prior representations, agreements and understandings (including any prior course of dealings),
both written and oral, between you and the Company with respect to the subject matter hereof. In the event of any inconsistency
between this offer letter and any other plan, program, practice or agreement in which you are a participant or a party, this offer
letter shall control unless such other plan, program, practice or agreement is more favorable to you (term by term) or specifically
refers to this offer letter as not controlling.

 

This offer
letter and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively
or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by you and the Company. This
offer letter and your rights and obligations hereunder, may not be assigned by you, and any purported assignment by you in violation
hereof shall be null and void. The Company is authorized to assign this offer letter to a successor to substantially all of its
assets or business. Nothing in this offer letter shall confer upon any person not a party hereof, or the legal representatives
of such person, any rights or remedies of any nature or kind whatsoever under or by reason of this offer letter, except the personal
representative of the deceased. This offer letter shall inure to the benefit of, and be binding on, the successors and assigns
of each of the parties, including, without limitation, your heirs and the personal representatives of your estate and any successor
to all or substantially all of the business and/or assets of the Company.

 

    7

     

    

 

No remedy
conferred upon a party by this offer letter is intended to be exclusive of any other remedy, and each and every such remedy shall
be cumulative and shall be in addition to any other remedy given under this offer letter or now or hereafter existing at law or
in equity. Except as explicitly provided herein, no delay or omission by a party in exercising any right, remedy or power under
this offer letter or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.

 

This offer
letter shall be construed and enforced in accordance with, and the laws of the State of New York, without giving effect to the
conflicts of law principles thereof.

 

Any reference
to a Section of the Code shall be deemed to include any successor to such Section.

 

This offer letter and the compensation payable
hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may
be implemented by the Board from time to time with respect to officers of the Company.

 

Any notices required or permitted hereunder
or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered
or mailed by registered or certified mail, if to the Company, to the CEO at the address above, and if to you at the most recent
address in the Company’s records.

 

Please acknowledge
your acceptance of this offer by returning a signed copy of this offer letter. If there are any other agreements of any type that
you are aware of that may impact or limit your ability to perform your job at the Company, please let us know as soon as possible.
In accepting this offer, you represent and warrant to the Company that you are not subject to any legal or contractual restrictions
that would in any way impair your ability to perform your duties and responsibilities to the Company, and that all information
you provided to the Company is accurate and complete in all respects. This offer will remain open until October 4, 2018.

 

Formalities
aside, we are very excited about having you join our team. Your skills and experiences are a great match with our goals, and I
anticipate you being a critical part of the Company’s success.

 

Very truly yours,

 

/s/ Carsten Thiel, Ph.D.

Carsten Thiel, Ph.D.

Chief Executive Officer

Abeona Therapeutics
Inc.

 

I accept this
offer of employment with Abeona Therapeutics and will begin employment on October 24, 2018.

 

 

	Signature:	 	Date:	 
	 	 	 	 
	/s/ João Siffert, M.D.	 	4 - Oct - 2018	 

 

    8

     

    

 

Exhibit A

 

EMPLOYEE CONFIDENTIALITY, NON-COMPETITION,
AND

PROPRIETARY INFORMATION AGREEMENT

 

THIS AGREEMENT, effective as of 24 October,
2018 between Abeona Therapeutics Inc., a Delaware corporation (the “Company”), and Joao Siffert, MD
(the “Employee”).

 

1.              
Employee will make full and prompt disclosure to the Company of all inventions, improvements, modifications, discoveries,
methods, technologies, biological materials, and developments, and all other materials, items, techniques, and ideas related directly
or indirectly to the business of the Company (collectively, “Intellectual Property”), whether patentable or
not, made or conceived by Employee or under Employee’s direction during Employee’s employment with the Company, whether
or not made or conceived during normal working hours, or on the premises of the Company.

 

2.              
Employee agrees that all Intellectual Property, as defined above, shall be the sole property of the Company and its assigns,
and the Company and its assigns shall be the sole owner of all patents and other rights in connection therewith. Employee hereby
assigns to the Company any rights Employee may have or acquire in all Intellectual Property and all related patents, copyrights,
trademarks, trade names, and other industrial and intellectual property rights and applications therefore, in the United States
and elsewhere. Employee further agrees that with regard to all future developments of Intellectual Property, Employee will assist
the Company in every way that may be reasonably required by the Company (and at the Company’s expense) to obtain and, from
time to time, enforce patents on Intellectual Property in any and all countries that the Company may require, and to that end,
Employee will execute all documents for use in applying for and obtaining such patents thereon and enforcing the same, as the Company
may desire, together with any assignment thereof to the Company or persons designated by the Company, and Employee hereby appoints
the Company as Employee’s attorney to execute and deliver any such documents or assignments requested by the Company. Employee’s
obligation to assist the Company in obtaining and enforcing patents for Intellectual Property in any and all countries shall continue
beyond the termination of Employee’s employment with the Company, but the Company shall compensate Employee at a reasonable,
standard hourly rate following such termination for time directly spent by Employee at the Company’s request for such assistance.

 

3.              
Employee hereby represents that Employee has no continuing obligation to assign to any former employer or any other person,
corporation, institution, or firm any Intellectual Property as described above. Employee represents that Employee’s performance
of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence
proprietary information acquired by Employee, in confidence or in trust, prior to Employee’s employment by the Company. Employee
has not entered into, and Employee agrees not to enter into, any agreement (either written or oral), which would put Employee in
conflict with this Agreement.

 

4.              
Employee agrees to assign to the Company any and all copyrights and reproduction rights to any material prepared by Employee
in connection with this Agreement and/or developed during the term of Employee’s employment with the Company.

 

5.              
Employee understands and agrees that a condition of Employee’s employment and continued employment with the Company
is that Employee has not brought and will not bring to the Company or use in the performance of Employee’s duties at the
Company any materials or documents rightfully belonging to a former employer which are not generally available to the public.

 

    A-1

     

    

 

6.              
Employee recognizes that the services to be performed by Employee hereunder are special, unique, and extraordinary and that,
by reason of Employee’s employment with the Company, Employee may acquire Confidential Information (as hereinafter defined)
concerning the operation of the Company, the use or disclosure of which would cause the Company substantial loss and damage which
could not be readily calculated and for which no remedy at law would be adequate. Accordingly, except as provided in the last Paragraph
in this Section 6, Employee agrees that Employee will not (directly or indirectly) at any time, whether during or after Employee’s
employment with the Company:

 

		(i)	knowingly use for personal benefit or for any other reason not authorized
by the Company any Confidential Information that Employee may acquire or has acquired by reason of Employee’s employment
with the Company, or;

 

		(ii)	disclose any such Confidential Information to any person or entity except
(A) in the performance of Employee obligations to the Company hereunder, (B) as required by a court of competent jurisdiction,
or (C) with the prior consent of the Board of Directors of the Company.

 

As used
herein, “Confidential Information” includes information with respect to the facilities and methods of the Company,
reagents, chemical compounds, cell lines or subcellular constituents, organisms, or other biological materials, trade secrets,
and other Intellectual Property, systems, patents and patent applications, procedures, manuals, confidential reports, financial
information, business plans, prospects, or opportunities, personnel information, or lists of customers and suppliers; provided,
however, that Confidential Information shall not include any information that is known or becomes generally known or available
publicly other than as a result of disclosure by Employee which is not permitted as described in clause (ii) above, or the Company
discloses same to others without obtaining an agreement of confidentiality.

 

Employee
confirms that all Confidential Information is the exclusive property of the Company. All business records, papers, documents and
electronic materials kept or made by Employee relating to the business of the Company which comprise Confidential Information shall
be and remain the property of the Company during the Employee’s employment and at all times thereafter. Upon the termination,
for any reason, of Employee’s employment with the Company, or upon the request of the Company at any time, Employee shall
deliver to the Company, and shall retain no copies of any written or electronic materials, records and documents made by Employee
or coming into Employee’s possession concerning the business or affairs of the Company and which comprise Confidential Information.
To the extent that, upon termination, Employee has any Confidential Information or other proprietary material of the Company stored
within any PDA or personal computer, email account, thumb drive or other storage device or cloud storage, Employee agrees to fully
cooperate with the Company to return such information and material and subsequently permanently delete and remove such information
and material from such devices (subject to any litigation preservation directive in effect), including, as necessary, providing
access by the Company to such devices to ensure compliance with this Paragraph.

 

    A-2

     

    

 

Nothing in
this Agreement shall prohibit or restrict Employee from lawfully (a) initiating communications directly with, cooperating with,
providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental
or regulatory agency, entity, or officials, including the Food and Drug Administration, the Securities and Exchange Commission
and the Equal Employment Opportunity Commission (collectively, “Governmental Authorities”) regarding a possible
violation of any law; (b) responding to any inquiry or legal process directed to Employee individually (and not directed to
the Company) from any such Governmental Authorities; (c) testifying, participating or otherwise assisting in an action or proceeding
by any such Governmental Authorities relating to a possible violation of law; or (d) making any other disclosures that are protected
under the whistleblower provisions of any applicable law. Notwithstanding the foregoing, Employee agrees that in making any such
disclosures or communications, Employee will take all reasonable precautions to prevent any unauthorized use or disclosure of any
information that may constitute Company Confidential Information to any parties other than any Governmental Authority. Employee
further understands that Employee is not permitted to disclose the Company’s attorney-client privileged communications or
attorney work product unless required by applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016,
Employee shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade
secret that: (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or
to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made to Employee’s
attorney in relation to a lawsuit for retaliation against Employee for reporting a suspected violation of law; or (iii) is made
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement
require Employee to obtain prior authorization from the Company before engaging in any conduct described in this Paragraph, or
to notify the Company that you have engaged in any such conduct.

 

7.              
During the term of Employee’s employment with the Company and for one (1) year thereafter (the “Restricted
Period”), the Employee shall not directly or indirectly, for Employee’s own account or for the account of others,
as an officer, director, stockholder (other than as the holder of less than 1% of the outstanding stock of any publicly traded
company), owner, partner, employee, promoter, investor, consultant, manager or otherwise participate in the promotion, financing,
ownership, operation, or management of, or assist in or carry on through proprietorship, a corporation, partnership, or other form
of business entity which is in competition with the Company in the field of RNA interference (RNAi) (the “Company Business”)
within the United States or any other country in which the Company is conducting or is actively seeking or planning to conduct
the Company Business as of the date of such termination.

 

During the
Restricted Period, the Employee shall not, whether for Employee’s own account or for the account of any other person (excluding
the Company): (i) solicit or contact in an effort to do business with any person who was or is a customer or prospective customer
(i.e., any individual or entity with whom the Company was actively engaged in soliciting to do business) of the Company, or any
affiliate of the Company, at the time of Employee’s termination or at any time during the two (2) year period prior to Employee’s
termination, if such solicitation or contact is for the purpose of competition with the Company; or (ii) solicit or induce any
of the Company’s employees to leave their employment with the Company or accept employment with anyone else, or hire any
such employees or persons who were employed by the Company during the preceding twelve (12) months.

 

Nothing herein
shall prohibit or preclude the Employee from performing any other types of services that are not precluded by this Section 7 for
any other person.

 

    A-3

     

    

 

Employee
has carefully read and considered the provisions of this Section 7 (including the Restricted Period, scope of activity to be restrained,
and the restriction’s geographical scope) and concluded them to be fair, appropriate and reasonably required for the protection
of the legitimate business interests of the Company, its officers, directors, employees, creditors, and shareholders. Employee
understands that the restrictions contained in this Section 7 may limit Employee’s ability to engage in a business similar
to the Company’s business, but acknowledges that Employee will receive adequate and affluent remuneration and other benefits
from the Company hereunder to justify such restrictions.

 

The Employee
shall give prompt notice to the Company of the Employee’s acceptance of employment or other fees for services relationship
during the Restricted Period, which notice shall include the name of, the business of, and the position that Employee shall hold
with such other employer. Employee also agrees to inform any prospective employer or business entity or person of the restrictions
set forth in this Agreement prior to accepting employment or entering into any business relationship.

 

8.              
In the event that Employee’s employment is transferred by the Company to a subsidiary, affiliated company, or acquiring
company (as the case may be), Employee’s employment by such company will, for the purpose of this Agreement, be considered
as continued employment with the Company, unless Employee executes an agreement, substantially similar in substance to this Agreement,
and until the effective date of said agreement in any such company for which Employee becomes employed. It is likewise agreed that
no changes in Employee’s position or title will operate to terminate the provisions of this Agreement unless expressly agreed
to in writing.

 

9.              
Upon termination of Employee’s employment for any reason, unless such employment is transferred to a subsidiary, affiliated
or acquiring company of the Company, Employee agrees to leave with, or return to, the Company all records, drawings, notebooks,
and other documents pertaining to the Company’s Confidential Information, whether prepared by Employee or others, as well
as any equipment, tools or other devices owned by the Company, that are then in Employee’s possession, however such items
were obtained, and Employee agrees not to reproduce or otherwise retain any document or data relating thereto.

 

10.           
Subject to Section 6 with respect to disclosure to Governmental Authorities, Employee agrees and covenants that he will
not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks,
comments, or statements concerning the Company or its businesses, or any of its employees, officers, and existing and prospective
customers, suppliers, investors and other associated third parties. The Company agrees and covenants that it will instruct its
Board members and executive officers to not at any time make, publish or communicate to any person or entity or in any public forum
any defamatory or disparaging remarks, comments, or statements concerning Employee or his or her business.

 

11.           
Employee’s obligations under this Agreement shall survive the termination of Employee’s employment with the
Company regardless of the manner of, and reason for, such termination or resignation, and shall be binding upon Employee’s
heirs, executors, and administrators.

 

12.           
Prior to entering the employ of the Company, Employee has lawfully terminated employment with all previous employers. Employee
acknowledges that this Agreement does not constitute a contract of employment for a term and does not otherwise imply that the
Company will continue his or her employment for any period of time.

 

    A-4

     

    

 

13.           
Employee agrees that there is no Intellectual Property relevant to the subject matter of Employee’s employment with
the Company, which has been made or conceived or first reduced to practice by Employee alone or jointly with others prior to Employee’s
employment with the Company, which Employee desires to exclude from Employee’s obligations under this Agreement.

 

14.           
No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any
other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed
as a bar to or waiver of any right on any other occasion.

 

15.           
Employee agrees that in addition to any other rights and remedies available to the Company for any breach or threatened
breach by Employee of Employee’s obligations hereunder, the Company shall be entitled to enforcement of Employee’s
obligations hereunder by whatever means are at the Company’s disposal, including court injunction, without having to post
a bond or other security. In the event of any such breach or threatened breach by Employee, the Company shall be entitled to recover
all of its reasonably incurred costs and attorney’s fees in enforcing its rights hereunder, and the Restricted Period shall
be extended by the period of any such breach.

 

16.           
The Company may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation
or otherwise) all or substantially all of the business and/or assets of the Company. Employee shall have no rights of assignment.

 

17.           
If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then such provision shall be enforceable
to the extent that a court deems it reasonable to enforce such provision. If such provision shall be unreasonable to enforce to
any extent, such provision shall be severed and all remaining provisions shall continue in full force and effect.

 

18.           
Employee hereby acknowledges receipt of the Company’s Confidentiality Policy.

 

19.           
This Agreement shall be effective as of the date set forth below next to Employee’s signature.

 

20.           
This Agreement and the employment offer letter constitute the entire contract between the parties hereto with regard to
the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and
whether express or implied) which relate to the subject matter hereof.

 

21.           
This Agreement shall be governed in all respects by the laws of the State of New York. Each of the Company and Employee
(a) hereby irrevocably submits to the exclusive jurisdiction of the state courts of the State of New York or the United States
District Court located in New York, New York for the purpose of any action between the Company and Employee arising in whole or
in part under or in connection with this Agreement, (b) hereby waives, to the extent not prohibited by applicable law, and agrees
not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to
the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action
brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred or removed
to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in
any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced
in or by such court, and (c) hereby agrees not to commence any such action other than before one of the above-named courts. Notwithstanding
the previous sentence, the Company or Employee may commence any action in a court other than the above-named courts solely for
the purpose of enforcing an order or judgment issued by one of the above-named courts.

 

    A-5

     

    

 

IN WITNESS
WHEREOF, Employee has executed this Agreement under seal as of the date set forth above:

 

EMPLOYEE

 

 

By:   /s/ Joao Siffert, MD           

 

Name: Joao Siffert, MD

 

 

ACCEPTED AND AGREED TO BY THE COMPANY:

 

 

By: /s/ Carsten Thiel, Ph.D.                      

 

Name: Carsten Thiel, Ph.D.

 

Title: Chief Executive Officer

 

    A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]